ATE353906T1 - Cd27 ligand - Google Patents

Cd27 ligand

Info

Publication number
ATE353906T1
ATE353906T1 AT93920446T AT93920446T ATE353906T1 AT E353906 T1 ATE353906 T1 AT E353906T1 AT 93920446 T AT93920446 T AT 93920446T AT 93920446 T AT93920446 T AT 93920446T AT E353906 T1 ATE353906 T1 AT E353906T1
Authority
AT
Austria
Prior art keywords
cd27l
ligand
polypeptide
vectors
receptor
Prior art date
Application number
AT93920446T
Other languages
English (en)
Inventor
M Patricia Beckmann
Raymond G Goodwin
Judith G Giri
Richard J Armitage
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE353906T1 publication Critical patent/ATE353906T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Registering, Tensioning, Guiding Webs, And Rollers Therefor (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT93920446T 1992-09-08 1993-09-01 Cd27 ligand ATE353906T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94164892A 1992-09-08 1992-09-08
US08/106,507 US5573924A (en) 1992-09-08 1993-08-13 CD27 ligand

Publications (1)

Publication Number Publication Date
ATE353906T1 true ATE353906T1 (de) 2007-03-15

Family

ID=26803747

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93920446T ATE353906T1 (de) 1992-09-08 1993-09-01 Cd27 ligand

Country Status (9)

Country Link
US (1) US5573924A (de)
EP (1) EP0662077B1 (de)
JP (1) JP3559281B2 (de)
AT (1) ATE353906T1 (de)
AU (1) AU5099293A (de)
CA (1) CA2144056C (de)
DE (1) DE69334111T2 (de)
ES (1) ES2281896T3 (de)
WO (1) WO1994005691A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) * 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US6599719B2 (en) 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US6824767B2 (en) 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5994503A (en) * 1995-03-27 1999-11-30 Yale University Nucleotide and protein sequences of lats genes and methods based thereon
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6010853A (en) * 1997-05-29 2000-01-04 Dana-Farber Cancer Institute Siva genes, novel genes involved in CD27-mediated apoptosis
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003009862A1 (en) * 2001-07-20 2003-02-06 Genset S.A. Agonists and antagonists of modumet for use in the treatment of metabolic disorders
US20050118656A1 (en) * 2001-11-27 2005-06-02 Terrett Jonathan A. Methods for diagnosis and treatment of epithelial-derived cancers
US7261892B2 (en) * 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
JP2005530482A (ja) * 2002-01-04 2005-10-13 ゼンコー・インコーポレイテッド ドミナントネガティブタンパク質およびそれらの用法
US20040170602A1 (en) * 2002-01-04 2004-09-02 Desjarlais John R. Dominant negative proteins and methods thereof
SG108837A1 (en) * 2002-03-11 2005-02-28 Pi Eta Consulting Co Pte Ltd An enterprise knowledge and information acquisition, management and communications system with intelligent user interfaces
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
DK1594542T3 (da) * 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
US20050282168A1 (en) * 2003-09-29 2005-12-22 Wyeth Cell surface molecules as markers and therapeutic agents against kidney cancers
EP1799262A4 (de) * 2004-10-15 2009-10-21 Seattle Genetics Inc Anti-cd70-antikörper und seine verwendung zur behandlung und vorbeugung von krebserkrankungen und immunstörungen
US8337838B2 (en) * 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) * 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP1871418B1 (de) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanisierte, anti-cd70-bindende wirkstoffe und ihre verwendung
NZ566395A (en) * 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
AU2007333098A1 (en) * 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind CD70 and uses thereof
EP2090320A1 (de) 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Liganden des natürlichen Killer Zelloberflächenmarkers CD27 und therapeutische Verwendungen davon
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
EP3103875A1 (de) * 2008-07-21 2016-12-14 Apogenix AG Einkettige tnfsf-moleküle
SG181938A1 (en) 2009-12-25 2012-07-30 Pharmalogicals Res Pte Ltd Method for searching and screening for target of anti-cancer agent using non-human animal model having nog established cancer cell line transplanted therein
CN103328626B (zh) 2010-10-06 2017-02-08 中外制药株式会社 癌干细胞群及其制备方法
PL2686347T3 (pl) 2011-03-16 2018-10-31 Argenx Bvba Przeciwciała przeciwko CD70
WO2013035824A1 (ja) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞の分離
ES2806146T3 (es) 2011-09-22 2021-02-16 Amgen Inc Proteínas de unión al antígeno CD27L
EP2772268B8 (de) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Krebsstammzellenspezifisches molekül
BR122020002414B1 (pt) 2012-03-15 2022-03-03 Janssen Biotech, Inc Uso de anticorpos anti-cd27 humanos
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2017058850A1 (en) 2015-09-28 2017-04-06 Regents Of The University Of Minnesota Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
EP3364995B1 (de) * 2015-10-23 2021-08-04 Apogenix AG Einkettige cd27-rezeptor-agonisten-proteine
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US20240150472A1 (en) 2021-03-17 2024-05-09 Daiichi Sankyo Company, Limited Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
CN119143876B (zh) * 2024-10-09 2025-09-16 武汉海沙百得生物技术有限公司 一种抗cd27l的全人源抗体或抗体片段及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5573924A (en) * 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
ATE240394T1 (de) * 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine

Also Published As

Publication number Publication date
AU5099293A (en) 1994-03-29
WO1994005691A1 (en) 1994-03-17
EP0662077A4 (de) 1997-01-08
US5573924A (en) 1996-11-12
JPH08500976A (ja) 1996-02-06
DE69334111D1 (en) 2007-03-29
CA2144056C (en) 2010-04-13
DE69334111T2 (de) 2007-11-22
CA2144056A1 (en) 1994-03-17
EP0662077B1 (de) 2007-02-14
ES2281896T3 (es) 2007-10-01
EP0662077A1 (de) 1995-07-12
JP3559281B2 (ja) 2004-08-25

Similar Documents

Publication Publication Date Title
DE69334111D1 (en) Cd27 ligand
DE69334100D1 (de) Elk ligand, ein cytokin
DE69433552D1 (de) An den zelloberflächenrezeptor hek bindendes cytokin
ATE286907T1 (de) Cytokinin-designiertes lerk-5
AU4639396A (en) Cytokine designated lerk-7
GB9518323D0 (en) Materials and methods relating to the attachment and display of substances on cell surfaces
EP1676857A3 (de) Trail bindender Rezeptor
DK0832229T3 (da) CD40L-mutein
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
DE69737978D1 (de) Als 2f1 bezeichnetes rezeptorprotein
IL132496A0 (en) Mammalian cytokine-like factor 7
EP0739350A4 (de) Fas-antigenbindender ligand
DE69014474D1 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
MX9700213A (es) Citocina novedosa designada como lerk-5.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties